GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TNF Pharmaceuticals Inc (LTS:0A8D) » Definitions » Equity-to-Asset

TNF Pharmaceuticals (LTS:0A8D) Equity-to-Asset : 0.69 (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is TNF Pharmaceuticals Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. TNF Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $14.72 Mil. TNF Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2024 was $21.42 Mil.

The historical rank and industry rank for TNF Pharmaceuticals's Equity-to-Asset or its related term are showing as below:

LTS:0A8D' s Equity-to-Asset Range Over the Past 10 Years
Min: -7.77   Med: 0.72   Max: 0.95
Current: 0.69

During the past 5 years, the highest Equity to Asset Ratio of TNF Pharmaceuticals was 0.95. The lowest was -7.77. And the median was 0.72.

LTS:0A8D's Equity-to-Asset is ranked better than
53.06% of 1504 companies
in the Biotechnology industry
Industry Median: 0.67 vs LTS:0A8D: 0.69

TNF Pharmaceuticals Equity-to-Asset Historical Data

The historical data trend for TNF Pharmaceuticals's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TNF Pharmaceuticals Equity-to-Asset Chart

TNF Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Equity-to-Asset
-7.77 0.95 0.84 0.72 0.69

TNF Pharmaceuticals Quarterly Data
Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.72 0.71 0.01 0.71 0.69

Competitive Comparison of TNF Pharmaceuticals's Equity-to-Asset

For the Biotechnology subindustry, TNF Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TNF Pharmaceuticals's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TNF Pharmaceuticals's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where TNF Pharmaceuticals's Equity-to-Asset falls into.


;
;

TNF Pharmaceuticals Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

TNF Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Equity to Asset (A: Dec. 2024 )=Total Stockholders Equity/Total Assets
=14.72/21.421
=

TNF Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

Equity to Asset (Q: Dec. 2024 )=Total Stockholders Equity/Total Assets
=14.72/21.421
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TNF Pharmaceuticals  (LTS:0A8D) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


TNF Pharmaceuticals Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of TNF Pharmaceuticals's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


TNF Pharmaceuticals Business Description

Traded in Other Exchanges
Address
855 North Wolfe Street, Suite 601, Baltimore, MD, USA, 21205
TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B.

TNF Pharmaceuticals Headlines

No Headlines